A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Recruiting now Phase 3 NCT06615479
Run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · for 18 and older · All sexes
What this study is about
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Who can join (things the study team will check)
✅ You may be able to join if…
- Participants must have relapsed or refractory multiple myeloma (RRMM).
- Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody and have prior exposure to lenalidomide.
- Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria.
- Participants must have measurable disease during screening.
- Participants must have adequate organ function.
- Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.
🚫 You may not be able to join if…
- Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM).
- Participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease.
- Participants must not need urgent treatment due to rapidly progressing MM.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where this trial is running
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange, California, United States
- Local Institution - 0223, Washington D.C., District of Columbia, United States
- Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida, United States
- Local Institution - 0228, Orlando, Florida, United States
- Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
- Louisiana State University Health Sciences Shreveport, Shreveport, Louisiana, United States
- Boston Medical Center, Boston, Massachusetts, United States
- Local Institution - 0219, Minneapolis, Minnesota, United States
- Weill Cornell Medical College, New York, New York, United States
+ 128 more sites.
Who to contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06615479.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.